IBM Insight 2015 with Bionik Laboratories

Bionik Laboratories’ ARKE™ exoskelton, in partnership with IBM, has developed a cloud-based data collection and analysis system that runs on the IBM Bluemix cloud system.

Bionik Laboratories (OTCQX: BNKL) is a pioneering medical device and robotics company developing transformational robotic rehabilitation technologies for individuals with neurological disorders. The company is dedicated to providing individuals with restricted mobility an improvement in overall health, comfort, accessibility, and quality of life through the commercialization of its proprietary products.

The company’s lead program, ARKE™ is the most comprehensive lower-body exoskeleton that allows paraplegics and as well as other wheelchair users the ability to rehabilitate through walking. Currently in clinical development, ARKE will initially be used in a rehabilitation environment, with the goal of being made available for home use.

ARKE GEN2 is Bionik’s novel and proprietary second generation robotic lower-body exoskeleton, designed with a lighter mechanical profile from the Company’s first generation and significantly improved control, adaptability, safety and electronics.

“Bionik’s patented ARKE exoskeleton has the ability to allow users to walk more easily and efficiently. Currently, there are approximately 10 million wheelchair users in developed countries and a large percentage of people could be directly affected by ARKE rehabilitation,” remarked Michal Prywata, the Company’s Co-Founder and Chief Operating Officer. “With robotic exoskeletons like ARKE, we have the potential to transform the future for mobility impaired patients by significantly improving rehabilitation stimulation.”

ARKE units are expected to be shipped to rehabilitation centers in Canada and clinical evaluation is expected to commence before year end. Bionik expects to report initial findings from the use of the second generation robotic device by mid-2016.

In preparation for the launch of the ARKE rehabilitation clinical validation program, Bionik expects to commence pre-clinical verification testing in early 2016. The Company then anticipates filing for the appropriate regulatory approvals for ARKE with Health Canada, the European Medicines Agency (EMA) and United States Food and Drug Administration (FDA) filings are expected to follow.

Bionik Laboratories Website for additional information is HERE.

This entry was posted in Chronic Spinal Cord Injury Research, Rehabilitation, Spinal Research and tagged , , , . Bookmark the permalink.